For BioNTech, the third quarter is where the year's revenue is made or lost. Second-quarter sales were just $122.8 million, and first-half revenue totaled only €224 million. That makes the upcoming report, due before the open on November 3, the first real test of the COVID-19 demand assumptions behind last quarter's sharp guidance cut. The question is whether management cut deep enough or whether the vaccine franchise has further to fall.

Wall Street expects earnings of $0.85 per share on revenue of $1.17 billion. That would be a swing to profit from a loss of $0.14 a year ago, but revenue would fall about 34% from $1.78 billion. The headline EPS growth figure looks spectacular only because the starting point was negative. The real story is a shrinking top line, partly offset by a leaner cost structure. Management trimmed adjusted R&D guidance to €2.0 billion to €2.3 billion, and that lower spending helps explain how profit can rise while sales fall. Restructuring and impairment charges tied to the manufacturing consolidation weighed on recent results and could again blur the reported bottom line.

The guidance comparison is where the tension sits. BioNTech now expects 2026 revenue of $1.84 billion to $2.19 billion, down from $2.34 billion to $2.69 billion. That was roughly an 18% cut at the midpoint, after the original range had been reaffirmed only a quarter earlier. Yet the full-year consensus still sits near $2.49 billion, above even the top of the new range. Some of that likely reflects estimates that have not been updated. Still, it means a quarter that merely tracks guidance could read as a miss against stale full-year numbers.

Management blamed about 80% of the cut on weaker global COVID-19 demand. European regulators allowed last year's formula to remain in use, and Germany chose to draw down doses it already had, which hits sales BioNTech books directly. The rest came from an out-licensing milestone that will no longer arrive in 2026. This quarter's numbers will show whether those were contained, one-time issues or signs of broader erosion. Revenue near or above $1.17 billion, plus a reaffirmed range, would suggest last quarter's reset was realistic. A shortfall, or another trim to the outlook, would raise doubts about how well management can forecast its legacy business at a time of leadership change. Incoming CEO Guido Oelkers takes over by February 1 at the latest, and founders Ugur Sahin and Özlem Türeci plan to leave for a new mRNA venture by the end of 2026.

The oncology pipeline is the counterweight. Prometamic, the company's PD-L1/VEGF bispecific antibody, produced a 62.5% confirmed response rate in first-line lung cancer, including 47.6% in patients with low PD-L1 expression. The B7H3 antibody-drug conjugate has entered its first Phase 3. Three Phase 3 interim readouts are still slated for the second half of 2026, in squamous lung, head and neck, and breast cancer, along with the first data pairing Prometamic with the ADC in lung cancer. Two other readouts have already slipped to 2027, so any further delay would undercut the case that the pipeline can carry the story. With €16.6 billion in cash and only €152 million of a €1 billion buyback completed so far, the pace of repurchases is also worth checking.

Sentiment has drifted from mildly bullish to mildly bearish, and the stock has slightly lagged the market since the last report. At $88.12, shares sit well below the 200-day average of $97.50 and just above the post-report low of $87.36, a long way from the $120.33 high. The bar is low, but so is the patience. The report needs to show that the COVID decline has stabilized at the reset level and that the late-2026 oncology catalysts remain on schedule. That combination would allow the pipeline to take over the narrative.